Session » Vasculitis Poster II

Date: Monday, November 9, 2015

Time: 9:00AM-11:00AM

Meeting: 2015 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1960

a Structured and Extensive Training Program on Vascular Ultrasound, Results in an Excellent Agreement Between Ultrasound and Temporal Artery Biopsy in the Diagnosis of Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 1985

Abnormal B-Cell Distribution Is Improved By Tocilizumab Monotherapy in Patients with Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 1966

Active PMR and GCA Is Associated with Changes in Monocyte Subset Composition

9:00AM-11:00AM: Abstract Number: 1979

Baseline Data on Patients Enrolled in a Randomized, Double-Blind Trial of Tocilizumab in Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 1964

Biomarkers in Temporal Artery Biopsies and Sera of Patients with Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 1969

Can We Predict the Relapse of Giant Cell Arteritis?

9:00AM-11:00AM: Abstract Number: 1972

Cardiovascular and Cerebrovascular Disease and Social Deprivation in Patients with Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 1986

Clinical Efficacy of Tocilizumab in Polymyalgia Rheumatica: An OPEN-Label Study.

9:00AM-11:00AM: Abstract Number: 1959

Color Doppler Ultrasonography Appears to Perform Better Than Magnetic Resonance Angiography in the Diagnostics of Patients with Systemic Large Vessel Vasculitis

9:00AM-11:00AM: Abstract Number: 1957

Colour-Doppler Ultrasonography of Epiaortic Arteries in Patients with Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 1976

Corticosteroid Therapy in Giant Cell Arteritis, Predictors for Long-Term Remission

9:00AM-11:00AM: Abstract Number: 1990

Corticosteroid Use in Idiopathic Aortitis: A Systematic Review

9:00AM-11:00AM: Abstract Number: 1967

Deregulation of Interleukin-22 Pathway in Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 1958

Diagnostic Value of Ultrasonography-Derived Signs in Giant Cell Arteritis: Literature Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 1968

Distinct Distribution Patterns of Large Vessel Vasculitis Assessed with 18f-FDG PET/CT: Evidence from Principal Component and Cluster Analyses

9:00AM-11:00AM: Abstract Number: 1974

Do Patients with Giant Cell Arteritis Meet the 2011 United Kingdom Department of Health Guidance on Physical Activity?

9:00AM-11:00AM: Abstract Number: 1987

Dramatic Efficacy of Tocilizumab As First Line Therapy in Patients with Recent Polymyalgia Rheumatica (PMR): Results of the First Longitudinal Prospective Study

9:00AM-11:00AM: Abstract Number: 1988

Efficacy and Safety of Mizoribine for Polymyalgia Rheumatica: Analysis of 47 Cases

9:00AM-11:00AM: Abstract Number: 1973

Giant Cell Arteritis and Risk of Cerebrovascular Accident: A Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 1971

Healthcare Utilization and Direct Medical Costs of Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 1954

How Can We Use Ultrasound in the Diagnosis and Management of Patients with Giant Cell Arteritis?

9:00AM-11:00AM: Abstract Number: 1953

Identification of Genetic Factors Associated with Clinical Manifestations of Giant Cell Arteritis through a Stratified Large-Scale Analysis

9:00AM-11:00AM: Abstract Number: 1993

Imaging Findings of Cerebral Amyloid Angiopathy, Abeta-Related Angiitis (ABRA) and Cerebral Amyloid Angiopathy-Related Inflammation: A Single Institution 25 Year Experience

9:00AM-11:00AM: Abstract Number: 1984

Incidence and Intensity of 18fdg Uptake on Whole Body PET/CT in Patients with Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 1970

Incidence and Predictors of Thoracic Aortic Damage in Biopsy-Proven Giant Cell Arteritis: A Single-Institution Cohort Study

9:00AM-11:00AM: Abstract Number: 1981

Increased Extracellular Water Measured By Bioimpedance Analysis in Polymyalgia Rheumatica Patients – Sign of Volume Overload

9:00AM-11:00AM: Abstract Number: 1962

Inter-Rater Analysis of Ultrasound and Histological Findings in Patients with Suspected Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 1961

Interobserver Agreement on Ultrasonographic and Magnetic Resonance Angiography Findings in Patients with Large Vessel Vasculitis

9:00AM-11:00AM: Abstract Number: 1983

Interspinous Bursitis Evaluation By Ultrasound Is Very Useful for Diagnosis of Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 1952

Lack of Association of a 6.7 Kbp Deletion of LILRA3 with Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 1991

Large Vessel Involvement By IgG4-Related Disease

9:00AM-11:00AM: Abstract Number: 1977

Long-Term Survival of Methotrexate in Giant Cell Arteritis Patients in Clinical Practice

9:00AM-11:00AM: Abstract Number: 1992

Plasma Endothelin-1 Parallels the Vasoconstriction Phase in Reversible Cerebral Vasoconstriction Syndrome

9:00AM-11:00AM: Abstract Number: 1956

Risk of Cerebrovascular Accident in Patients with Polymyalgia Rheumatica: A Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 1975

Risk of Mortality of Patients with Giant Cell Arteritis: A Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 1982

Sonographic Scoring of the Synovial Components in the Shoulder Revealed That Shoulder Synovitis in PMR Patients Is Milder Than That in Elderly-Onset RA Patients with PMR-like Onset

9:00AM-11:00AM: Abstract Number: 1963

Specialty of Provider Referring for Temporal Artery Biopsy Affects the Likelihood of Giant Cell Arteritis (GCA) Diagnosis

9:00AM-11:00AM: Abstract Number: 1965

T Cell Activation, Proliferation and Differentiation Markers Lack Diagnostic Accuracy for Detecting Active GCA and PMR

9:00AM-11:00AM: Abstract Number: 1951

The Incidence Rate of Giant Cell Arteritis in Slovenia

9:00AM-11:00AM: Abstract Number: 1955

The Performance of Colour-Doppler Sonography of Temporal Arteries in Patients Suspect of Having Giant Cell Arteritis in Daily Clinical Practice

9:00AM-11:00AM: Abstract Number: 1980

Tocilizumab in Giant Cell Arteritis: A Multicentre Open-Label Study in France

9:00AM-11:00AM: Abstract Number: 1978

Tocilizumab in Refractory Large Vessel Vasculitis with Aorta Involvement. Study on 10 Patients Evaluated By Positron Emission Tomoghraphy

9:00AM-11:00AM: Abstract Number: 1989

Treatment of Refractory Non-Infectious Aortitis: Tocilizumab Compared to Antitnf Alfa Agents. Multicenter Study of 44 Patients

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].